You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Claims for Patent: 8,389,542

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,389,542

Title:	Dosage unit comprising a prostaglandin analog for treating constipation
Abstract:	A dosage unit for treating constipation in a human patient is described. The dosage unit of the invention includes a halogenated prostaglandin analog and a pharmaceutically suitable excipient. The dosage unit relieves constipation without substantial side effects. In particular, the dosage unit includes a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein the dosage unit contains the PG analog in an amount of 24 .mu.g+/-10%: ##STR00001##
Inventor(s):	Ueno; Ryuji (Potomac, MD), Patchen; Myra L. (Fairfax, VA)
Assignee:	Sucampo AG (Zug, CH)
Application Number:	13/330,942
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,389,542
Patent Claims:	1. A dosage unit comprising a prostaglandin (PG) analog represented by Formula (I) and/or its tautomers, and a pharmaceutically suitable excipient, wherein the dosage unit contains said PG analog in an amount of 24 .mu.g+/-10%: ##STR00014## where A.sub.1 and A.sub.2 are fluorine atoms and B is --COOH, including its pharmaceutically acceptable salts, esters or amides. 2. The dosage unit of claim 1, wherein said PG analog is the monocyclic tautomer of formula (I). 3. The dosage unit of claim 1, wherein said PG analog is the bi-cyclic tautomer of formula (I). 4. The dosage unit of claim 1, wherein said pharmaceutically suitable excipient is orally acceptable. 5. The dosage unit of claim 1, wherein said pharmaceutically suitable excipient is a medium chain fatty acid. 6. The dosage unit of claim 1, wherein B is --COOH. 7. The dosage unit of claim 1, which is suitable for use in a human patient. 8. The dosage unit of claim 7, which is suitable for use in relieving or preventing constipation. 9. The dosage unit of claim 5, wherein B is --COOH. 10. The dosage unit of claim 1, wherein the PG analog is present in an amount of 24 .mu.g. 11. The dosage unit of claim 10, wherein B is --COOH. 12. The dosage unit of claim 10, wherein said pharmaceutically suitable excipient is a medium chain fatty acid. 13. The dosage unit of claim 11, wherein said pharmaceutically suitable excipient is a medium chain fatty acid.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.